A1 Refereed original research article in a scientific journal
Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen
Authors: Tornio A, Niemi M, Neuvonen PJ, Backman JT
Publisher: SPRINGER
Publication year: 2007
Journal: European Journal of Clinical Pharmacology
Journal name in source: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Journal acronym: EUR J CLIN PHARMACOL
Volume: 63
Issue: 5
First page : 463
Last page: 469
Number of pages: 7
ISSN: 0031-6970
DOI: https://doi.org/10.1007/s00228-007-0273-9
Abstract
Objective: Ibuprofen, a nonsteroidal anti-inflammatory agent, is metabolised in vitro by cytochrome P450 (CYP) 2C8 and 2C9. We studied the possible effect of gemfibrozil, an in vivo inhibitor of CYP2C8, on the pharmacokinetics of ibuprofen in healthy volunteers.Methods: In a randomised two-phase crossover study, 10 healthy volunteers took 600 mg gemfibrozil or placebo orally twice daily for 3 days. On day 3, each subject ingested 400 mg of racemic ibuprofen. Plasma concentrations of ibuprofen enantiomers and gemfibrozil were measured.Results: Gemfibrozil raised the mean total area under the plasma concentration-time curve (AUC(0-infinity)) of R-ibuprofen by 34% (range -10 to 67%; P < 0.001). The elimination half-lives (t(1/2)) of R- and S-ibuprofen were increased by 54 and 34% (range 11-162% and 16-85%; P < 0.001) respectively. The other pharmacokinetic variables of R- and S-ibuprofen were not changed significantly. The AUC(0-infinity) ratio of R-ibuprofen to S-ibuprofen was increased by gemfibrozil (P < 0.001).Conclusion: Gemfibrozil moderately increases the AUC(0-infinity) of R-ibuprofen and prolongs its t(1/2), indicating that R-ibuprofen is partially metabolised by CYP2C8. The interconversion of R- to S-ibuprofen can explain the small effect of gemfibrozil on the t(1/2) of S-ibuprofen. The gemfibrozil-ibuprofen interaction is of limited clinical significance.
Objective: Ibuprofen, a nonsteroidal anti-inflammatory agent, is metabolised in vitro by cytochrome P450 (CYP) 2C8 and 2C9. We studied the possible effect of gemfibrozil, an in vivo inhibitor of CYP2C8, on the pharmacokinetics of ibuprofen in healthy volunteers.Methods: In a randomised two-phase crossover study, 10 healthy volunteers took 600 mg gemfibrozil or placebo orally twice daily for 3 days. On day 3, each subject ingested 400 mg of racemic ibuprofen. Plasma concentrations of ibuprofen enantiomers and gemfibrozil were measured.Results: Gemfibrozil raised the mean total area under the plasma concentration-time curve (AUC(0-infinity)) of R-ibuprofen by 34% (range -10 to 67%; P < 0.001). The elimination half-lives (t(1/2)) of R- and S-ibuprofen were increased by 54 and 34% (range 11-162% and 16-85%; P < 0.001) respectively. The other pharmacokinetic variables of R- and S-ibuprofen were not changed significantly. The AUC(0-infinity) ratio of R-ibuprofen to S-ibuprofen was increased by gemfibrozil (P < 0.001).Conclusion: Gemfibrozil moderately increases the AUC(0-infinity) of R-ibuprofen and prolongs its t(1/2), indicating that R-ibuprofen is partially metabolised by CYP2C8. The interconversion of R- to S-ibuprofen can explain the small effect of gemfibrozil on the t(1/2) of S-ibuprofen. The gemfibrozil-ibuprofen interaction is of limited clinical significance.
UTU Research Portal